Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for mAbs, and will highlight product-specific and patient-specific factors that modulate their pharmacokinetic (PK) behavior and need to be considered for successful clinical therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613179 | PMC |
| http://dx.doi.org/10.1002/psp4.12224 | DOI Listing |
Publication Analysis
Top Keywords
monoclonal antibodies
8
pharmacokinetics monoclonal
4
antibodies monoclonal
4
antibodies mabs
4
mabs developed
4
developed decades
4
decades backbone
4
backbone pharmacotherapeutic
4
pharmacotherapeutic interventions
4
interventions variety
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!